| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S7492 R53812 |
Van der Veere, 2020 | Cognition (Bayley Scales of Infant and Toddler Development (BSID)) - At 2.5 years | during pregnancy (anytime or not specified) | prospective cohort | unexposed (general population or NOS) | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only | 2.89 [1.39;6.01] | -/61 -/41 | - | 61 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8046 R53807 |
Batton, 2013 | Moderate-risk range of neurodevelopmental delay with the Bayley Infant Neuro-developmental Screener (BINS) at 24 months | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free | Adjustment: No Monotherapy: SSRI only | 0.61 [0.15;2.44] C | 5/19 7/19 | 12 | 19 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S7969 R53811 |
Oberlander, 2004 | Mental developmental index from Bayley scales of infant development - At 8 months | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only | 0.68 [0.25;1.86] | -/28 -/23 | - | 28 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S510 R53808 |
Casper, 2003 | Mental Development Index (Bayley Scales of Infant Development tested by a clinical child psychologist) at age from 6 months to 40 months | during pregnancy (anytime or not specified) | prospective cohort | unexposed, sick | Adjustment: No extrapolated (cont. endpoint) Monotherapy: no or not specified Unexposed sick: recent illness/treatment (during or juste before pregnancy or treatment stopped in view of pregnancy) | 1.64 [0.50;5.32] | -/31 -/13 | - | 31 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8013 R53809 |
Nulman - Fluoxetine (Controls exposed to TCA), 2002 | Mental development IQ with Bayley Scales of Infant Development-II at 15 and 30 months of age | throughout pregnancy | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only |
2.01 [0.80;5.05] excluded (control group) |
-/33 -/28 | - | 33 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S8014 R53810 |
Nulman - Fluoxetine (Controls unexposed, disease free), 2002 | Mental development IQ with Bayley Scales of Infant Development-II at 15 and 30 months of age | throughout pregnancy | prospective cohort | unexposed, disease free | Adjustment: No extrapolated (cont. endpoint) Monotherapy: SSRI only | 0.96 [0.34;2.73] | -/33 -/18 | - | 33 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 5 studies | 1.24 [0.65;2.36] | 12 | 172 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, disease free;
Asymetry test p-value = 0.1288 (by Egger's regression)
slope=2.5291 (1.0819); intercept=-4.4225 (2.1247); t=2.0815; p=0.1288
excluded 8013